Xiaoping Jiang

发表

FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine–Refractory Differentiated Thyroid Cancer

K. He, P. Keegan, R. Pazdur, 2015, Clinical Cancer Research.

Regulatory Issues : FDA U . S . Food and Drug Administration Approval Summary : Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed

P. Keegan, R. Pazdur, G. Blumenthal, 2016 .

Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate

R. Pazdur, V. Goodman, J. Gobburu, 2008, Clinical Cancer Research.

Ixabepilone in Combination with Capecitabine and as Monotherapy for Treatment of Advanced Breast Cancer Refractory to Previous Chemotherapies Report from the Fda

R. Pazdur, R. Lechleider, R. Justice, 2022 .

U.S. Food and Drug Administration Approval: Vismodegib for Recurrent, Locally Advanced, or Metastatic Basal Cell Carcinoma

P. Keegan, R. Pazdur, A. Russell, 2013, Clinical Cancer Research.

Loss of CDYL Results in Suppression of CTNNB1 and Decreased Endometrial Receptivity

P. Leung, Hsun‐Ming Chang, Aijun Zhang, 2020, Frontiers in Cell and Developmental Biology.

FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1

P. Keegan, R. Pazdur, G. Blumenthal, 2016, The oncologist.

FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non‐Small Cell Lung Cancers Harboring BRAF V600E Mutations

Reena Philip, K. Goldberg, P. Keegan, 2018, The oncologist.

FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation

Justin C. Earp, Amy McKee, R. Pazdur, 2014, Clinical Cancer Research.

U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.

S. Khozin, P. Keegan, R. Pazdur, 2014, The oncologist.

Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer.

R. Pazdur, J. Gobburu, R. Justice, 2006, Oncology.

Drp1 mediates high glucose-induced mitochondrial dysfunction and epithelial-mesenchymal transition in endometrial cancer cells.

Xiaoping Jiang, X. Sheng, Jing Guo, 2020, Experimental cell research.

Tasigna for Chronic and Accelerated Phase Philadelphia Chromosome–Positive Chronic Myelogenous Leukemia Resistant to or Intolerant of Imatinib

Richard Pazdur, Robert Justice, Christine Garnett, 2008, Clinical Cancer Research.

FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma

Jiang Liu, L. Fashoyin-Aje, Martha Donoghue, 2020, Clinical Cancer Research.

U.S. Food and Drug Administration Approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma.

P. Keegan, R. Pazdur, Martin H. Cohen, 2012, The oncologist.

Benefit‐Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib

Jiang Liu, K. Goldberg, P. Keegan, 2018, The oncologist.

Prognostic significance of artemin in gastric cancer and its role in tumorigenesis

Kai Chen, Xiaoping Jiang, Jing Guo, 2020, Translational cancer research.

U.S. Food and Drug Administration Approval: Vismodegib for Recurrent, Locally Advanced, or Metastatic Basal Cell Carcinoma

P. Keegan, R. Pazdur, A. Russell, 2013, Clinical Cancer Research.

U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.

S. Khozin, P. Keegan, R. Pazdur, 2014, The Oncologist.

Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate

R. Pazdur, V. Goodman, J. Gobburu, 2008, Clinical Cancer Research.

Ixabepilone in Combination with Capecitabine and as Monotherapy for Treatment of Advanced Breast Cancer Refractory to Previous Chemotherapies

R. Pazdur, R. Lechleider, R. Justice, 2008, Clinical Cancer Research.